Chromocell announces stock repurchase plan

Freehold, n.j., aug. 07, 2024 (globe newswire) -- chromocell therapeutics corporation (“chromocell”, or the “company”), (nyse american: chro), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the “board of directors”) has authorized a stock repurchase plan (the “repurchase plan”) of up to $250,000 of chromocell's common stock (“common stock”), which represents approximately 23% of the non-affiliate float based on the closing price of the company's common stock as of august 6, 2024. the repurchase plan does not obligate the company to acquire any particular amount of common stock, and it may be modified, extended or terminated by the board of directors at any time.
CHRO Ratings Summary
CHRO Quant Ranking